The routine clinical integration of individualized objective markers of disease activity in
those diagnosed with the neurodegenerative disorder amyotrophic lateral sclerosis is a key …

Objective biomarkers for the clinically heterogeneous adult-onset neurodegenerative disorder
amyotrophic lateral sclerosis are crucial to facilitate assessing emerging therapeutics and …

Objective To appraise the utility as biomarkers of blood antibodies and immune complexes
to neurofilaments and dipeptide repeat proteins, the products of translation of the most …

Monocytes expressing the inflammation suppressing active CD11b, a beta2 integrin, may
regulate neuroinflammation and modify clinical outcomes in amyotrophic lateral sclerosis (ALS)…

Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder
characterized by 3 frontal and temporal lobe atrophy, typically manifesting with behavioural or …

The neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal 2
dementia (FTD) reside on a clinical and pathological continuum. Heterogeneity in clinical 3 …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder associated with loss of
motor neuronal system integrity, resulting in progressive muscle weakness for which there is …

Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder characterized
by frontal and temporal lobe atrophy, typically manifesting with behavioural or language …

Objective To test antibody response and formation of immune-complexes to neurofilaments
and dipeptide-repeats, the translational products of the mutated C9orf72 gene, as potential …

Aims This study aimed to explore the non‐linear relationships between cell‐free microRNAs
(miRNAs) and their contribution to prediction of Frontotemporal dementia (FTD), an early …